Key result
Reintroducing antipsychotics after clozapine-induced NMS is linked to asymptomatic CK elevation.
Why the study?
Is it safe to reintroduce antipsychotics in a patient with prior clozapine-induced neuroleptic malignant syndrome?
Case Report (n=1)
Is it safe to reintroduce antipsychotics in a patient with prior clozapine-induced neuroleptic malignant syndrome?
Reintroduction of antipsychotics after clozapine-induced NMS may cause asymptomatic CK elevation.
Answers are grounded in this paper and cite their sources.
May cause asymptomatic CK elevation on re-challenge after clozapine NMS; hypothesis-generating and should not yet change practice.
We report a case of neuroleptic malignant syndrome (NMS) secondary to clozapine treatment in which re-introduction of two different antipsychotics led to elevation of creatinine kinase (CK) levels without associated symptoms of NMS. The significance of CK levels as a marker for NM S is discussed in the light of previous findings in this area. We suggest clinical guidelines for antipsychotic rechallenge after the occurrence of NMS.
No takes yet. Share an insight, caveat, or question.
Williams et al. (1997) conducted a case report in Clozapine-induced neuroleptic malignant syndrome (n=1). Reintroduction of two different antipsychotics was evaluated on Elevation of creatinine kinase (CK) levels and symptoms of NMS. Reintroduction of two different antipsychotics in a patient with clozapine-induced neuroleptic malignant syndrome led to elevated creatinine kinase levels without associated symptoms of NMS.
Synapse has enriched 10 related papers. Consider them for comparative context: